メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪肝炎 (NASH) 治療薬の世界市場:産業分析と将来展望

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook 2017-2026

発行 Koncept Analytics 商品コード 397981
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.20円で換算しております。
Back to Top
非アルコール性脂肪肝炎 (NASH) 治療薬の世界市場:産業分析と将来展望 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook 2017-2026
出版日: 2017年10月09日 ページ情報: 英文 70 Pages
概要

当レポートでは、世界の非アルコール性脂肪肝炎 (NASH) 治療薬の市場について分析し、疾患の概要や主な診断・治療方法、治療薬市場の動向見通し、種類別・地域別の詳細動向、今後の治療薬開発・治験の見込み、主な市場促進・抑制要因、主要企業のプロファイルなどについて調査・推計しております。

第1章 イントロダクション

  • 非アルコール性脂肪肝炎 (NASH)
  • 原因と症状
  • 診断方法
  • 治療方法

第2章 世界の非アルコール性脂肪肝炎 (NASH) 市場

  • 世界のNASH関連市場の予測
  • 世界のNASH関連市場の予測:薬剤クラス別
  • NASH治療用オフラベル医薬品市場の予測

第3章 世界のNASH治療薬市場

  • 世界のNASH治療薬市場の予測
  • 世界のNASH治療薬市場の予測:薬剤クラス別
  • 世界のNASH治療薬市場の予測:地域別
  • 世界のNASH治療薬市場:種類別

第4章 地域別のNASH市場

  • 米国
  • 欧州
  • その他

第5章 市場の力学

  • 成長促進因子
  • 主な動向と発展
  • 課題

第6章 競合情勢

第7章 企業プロファイル

目次

Non-alcoholic steatohepatitis or NASH is a form of liver disease that causes inflammation and accumulation of fat tissues in the liver. It resembles alcoholic liver disease but occurs to those who drink too little or no alcohol. NASH shows no symptoms and is also known as a "Silent" liver disease. NASH can lead to cirrhosis, in which liver is permanently damaged and scarred and after a certain point, no treatment can cure it and thus lead to death.

There are two types of fatty liver disease: alcoholic fatty liver disease and non-alcoholic fatty liver disease (NAFLD). When inflammation is present with accumulation of fat in the liver then it is referred as NASH. Obesity and diabetes are most common cause of NASH disease. It is a challenge for the patient to recognize the accumulation of fat in the liver as patient experience no such symptoms until reach the advanced stage of the disease. The diagnosis of NASH includes blood tests, MRI, X-rays and liver biopsy.

Treatment of NASH includes managing and improving the condition of NASH from being worse and is recommended to bring changes in lifestyle and also use of off label drugs to control and manage indications related to NASH. Currently there is no approved drug in the market but is expected to enter the market in 2020. Currently, there are five potential Phase III drugs in the market including Elafibranor, Ocaliva (OCA), Cenicriviroc (CVC), Selonsertib and Aramchol.

The global NASH market is expected to show significant growth after the introduction of therapeutics drugs in 2020. Growth of market will mainly be driven by increasing patient base, rise in obese population, increasing type-2 diabetic population and increasing health expenditure. However, growth of market will also be hindered by absence of effective diagnostics, costly drugs, regulatory challenges and undefined pathogenesis.

The report "Global NASH Drugs Market: Industry Analysis & Outlook (2017-2026)" analyzes the development of this market, with focus on the US and Europe region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Allergan Plc. (Tobira) and Gilead Sciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.

Table of Contents

1. Market Overview

  • 1.1 Nonalcoholic Steatohepatitis (NASH)
  • 1.2 Causes & Symptoms
  • 1.3 Diagnosis
  • 1.4 Treatment

2. Global NASH Market

  • 2.1 Global NASH Drugs Market Forecast by Value
  • 2.2 Global NASH Drugs Market Forecast by Drug Class
  • 2.3 Global NASH Off Label Drugs Market Forecast by Value

3. Global NASH Therapeutics Market

  • 3.1 Global NASH Therapeutics Market Forecast by Value
  • 3.2 Global NASH Therapeutics Market Forecast by Drug Type
  • 3.3 Global NASH Therapeutics Market Forecast by Region
  • 3.4 Global NASH Therapeutics Market by Type
    • 3.4.1 Global Elafibranor Revenue Forecast by Value
    • 3.4.2 Global Obeticholic Acid (OCA) Revenue Forecast by Value
    • 3.4.3 Global Obeticholic Acid (OCA) Revenue Forecast by Region
    • 3.4.4 Global Cenicriviroc (CVC) Revenue Forecast by Value
    • 3.4.5 Global Cenicriviroc (CVC) Revenue Forecast by Region
    • 3.4.6 Global Aramchol Revenue Forecast by Value

4. Regional NASH Market

  • 4.1 The US
    • 4.1.1 The US NASH Therapeutics Market Forecast by Value
  • 4.2 The Europe
    • 4.2.1 Europe NASH Therapeutics Market Forecast by Value
  • 4.3 ROW
    • 4.3.1 ROW NASH Therapeutics Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Rising Patient Base
    • 5.1.2 Increasing Population with Type-2 Diabetes
    • 5.1.3 Escalating Obese Population
    • 5.1.4 Rising Healthcare Expenditure
    • 5.1.5 Increasing GDP Per Capita
    • 5.1.6 Vast Unmet Medical Need
  • 5.2 Key Trends & Development
    • 5.2.1 Strong Research & Development Efforts by Companies
    • 5.2.2 Development of NASH Diagnosis Methods and Biomarkers
  • 5.3 Challenges
    • 5.3.1 Absence of Low-Priced and Effective Diagnostics
    • 5.3.2 Regulatory Challenges and Undefined Pathogenesis
    • 5.3.3 Costly NASH Therapeutics

6. Competitive Landscape

  • 6.1 Revenue and Market Cap Comparison
  • 6.2 Major Pipeline Products

7. Company Profiles

  • 7.1 Genfit SA
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Intercept Pharmaceuticals
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Allergan (Tobira)
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Gilead Sciences
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies

List of Figures

  • Spectrum of Non-alcoholic Fatty Liver Disease (NAFLD)
  • Methods for NASH Diagnosis
  • Potential Phase III Drug Candidates
  • Global NASH Drugs Market Forecast by Value (2017-2026)
  • Global NASH Drugs Market Forecast by Drug Class (2017/2021/2026)
  • Global NASH Off Label Drugs Market Forecast by Value (2017-2026)
  • Global NASH Therapeutics Market Forecast by Value (2020-2026)
  • Global NASH Therapeutics Market Forecast by Drug Type (2021)
  • Global NASH Therapeutics Market Forecast by Drug Type (2026)
  • Global NASH Therapeutics Market Forecast by Region (2021)
  • Global NASH Therapeutics Market Forecast by Region (2026)
  • Global Elafibranor Revenue Forecast by Value (2020-2026)
  • Global Obeticholic Acid (OCA) Revenue Forecast by Value (2020-2026)
  • Global Obeticholic Acid (OCA) Revenue Forecast by Region (2026)
  • Global Cenicriviroc (CVC) Revenue Forecast by Value (2020-2026)
  • Global Cenicriviroc (CVC) Revenue Forecast by Region (2026)
  • Global Aramchol Revenue Forecast by Value (2022-2026)
  • The US NASH Therapeutics Market Forecast by Value (2020-2026)
  • Europe NASH Therapeutics Market Forecast by Value (2020-2026)
  • ROW NASH Therapeutics Market Forecast by Value (2020-2026)
  • The US NASH Market by Patient Population (2017-2026)
  • Global Type-2 Diabetes Population Forecast (2017-2026)
  • Global Obese Population (2012-2016)
  • Global Healthcare Expenditure Per Capita (2012-2016)
  • Global GDP Per Capita (2012-2016)
  • Genfit SA Revenue and Net Loss (2012-2016)
  • Genfit SA R&D Expenditure (2013-2016)
  • Intercept Pharmaceuticals Revenue and Net Income (2012-2016)
  • Intercept Pharmaceuticals R&D Expenditure (2013-2016)
  • Allergan (Tobira) Revenue by Segment (2016)
  • Allergan (Tobira) Revenue and Net Loss (2012-2016)
  • Allergan (Tobira) R&D Expenditure (2013-2016)
  • Gilead Sciences Revenue by Geographical Region (2016)
  • Gilead Sciences Revenue and Net Income (2012-2016)
  • Gilead Sciences R&D Expenditure (2013-2016)

List of Tables

  • Off Label Therapies for NASH (2016)
  • R&D Expenditure of Companies (2016)
  • Selected Diagnosis Methods in Development (2016)
  • NASH Key Players- Revenue and Market Cap Comparison (2016)
  • Key NASH Therapeutics Under Pipeline (2016)
  • Allergan (Tobira) Products Under Development for NASH (2016)
Back to Top